PCRX - Pacira Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.25
+0.25 (+0.68%)
At close: 4:00PM EDT

37.25 0.00 (0.00%)
After hours: 4:37PM EDT

Stock chart is not supported by your current browser
Previous Close37.00
Open37.00
Bid29.00 x 2200
Ask37.95 x 1400
Day's Range36.80 - 37.50
52 Week Range26.95 - 49.80
Volume297,601
Avg. Volume633,306
Market Cap1.517B
Beta1.87
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.82
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.

    Short interest is low for PCRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 13. Over the last one-month, outflows of investor capital in ETFs holding PCRX totaled $1.40 billion.

  • Pacira Focused on Exparel Development Amid Competition
    Zacks4 days ago

    Pacira Focused on Exparel Development Amid Competition

    Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.

  • Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
    Zacks9 days ago

    Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2

    Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.

  • GlobeNewswire10 days ago

    Pacira Reports Preliminary Net EXPAREL® Sales of $80.4 Million for Second Quarter of 2018

    Pacira Pharmaceuticals, Inc. (PCRX) today reported preliminary EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $80.4 million for the second quarter of 2018, a 15 percent increase over EXPAREL net product sales of $69.8 million reported in the second quarter of 2017. “We are excited to report another consecutive quarter of accelerating sales growth, representing the expanding adoption of EXPAREL as an integral component of multimodal, non-opioid pain management strategies in a variety of surgical procedures,” said Dave Stack, chairman and chief executive officer of Pacira. “Our Johnson & Johnson partnership is flourishing and we are continuing to see a high level of engagement and enthusiasm around the launch of EXPAREL as the first long-acting, single-dose nerve block for upper extremity surgeries with increasing demand from new and existing accounts.

  • See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.

    Short interest is moderate for PCRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 8. The net inflows of $2.85 billion over the last one-month into ETFs that hold PCRX are not among the highest of the last year and have been slowing.

  • ACCESSWIRE18 days ago

    Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks

    Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.

  • Investors Are Undervaluing Pacira Pharmaceuticals Inc (NASDAQ:PCRX) By 43.7%
    Simply Wall St.23 days ago

    Investors Are Undervaluing Pacira Pharmaceuticals Inc (NASDAQ:PCRX) By 43.7%

    In this article I am going to calculate the intrinsic value of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by estimating the company’s future cash flows and discounting them to their present value.Read More...

  • MarketWatch28 days ago

    Heron Therapeutics stock rockets 30% on high hopes for post-surgery pain treatment

    Heron Therapeutics Inc. shares surged 30% Thursday, after the company announced positive developments for its treatment for postoperative pain that aims to reduce patient dependence on opioids. It then said that its HTX-011, which was the focus of the two studies, has won breakthrough therapy designation from the U.S. Food and Drug Administration. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is intended for the management of postoperative pain.

  • GlobeNewswirelast month

    Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China

    Pacira Pharmaceuticals, Inc. (PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block.

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for Microchip Technology, New Jersey Resources, Brown-Forman, Pacira Pharmaceuticals, Team, and Solaris Oilfield Infrastructure — Fundamental Analysis, Key Performance Indications

    NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microchip ...

  • GlobeNewswirelast month

    Aetna DocFind Directory Now Highlights Providers Offering Opioid Alternatives, Including EXPAREL®

    Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (bupivacaine liposome injectable suspension), to manage postsurgical pain. This initiative builds off a national program launched by Pacira, Aetna, and the American Association of Oral and Maxillofacial Surgeons (AAOMS) in September 2017 aimed at reducing the number of opioid tablets prescribed to Aetna patients undergoing impacted wisdom tooth extractions through the use of EXPAREL.

  • Business Wirelast month

    MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS™) Collaborative to Minimize Opioid Use

    MEDNAX, Inc. (MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. (PCRX) to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as maternal and infant health, reduce the total cost of care and enhance provider satisfaction.

  • Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?
    Zacks2 months ago

    Pacira Pharmaceuticals (PCRX) Up 3.5% Since Earnings Report: Can It Continue?

    Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire2 months ago

    Pacira Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

    PARSIPPANY, N.J., May 31, 2018-- Pacira Pharmaceuticals, Inc. today reported that Dave Stack, chairman and chief executive officer, will present at the Jefferies 2018 Healthcare Conference at 9:30 AM ET ...

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks

    Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PCRX earnings conference call or presentation 3-May-18 12:30pm GMT

    Q1 2018 Pacira Pharmaceuticals Inc Earnings Call

  • Associated Press3 months ago

    Pacira: 1Q Earnings Snapshot

    On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 26 cents. Earnings, adjusted for stock option expense and amortization costs, were 2 cents per share. The results did ...

  • GlobeNewswire3 months ago

    Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results

    --EXPAREL ® net product sales of $74.0 million up 9% over prior year first quarter---- Conference call today at 8:30 a.m. ET--. PARSIPPANY, N.J., May 03, 2018-- Pacira Pharmaceuticals, Inc. today announced ...

  • GlobeNewswire3 months ago

    Pacira Pharmaceuticals to Present at Two Healthcare Conferences in May

    Pacira Pharmaceuticals, Inc. (PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.

  • GlobeNewswire3 months ago

    Pacira Pharmaceuticals Announces Timing for First Quarter 2018 Financial Results Webcast and Conference Call

    PARSIPPANY, N.J., April 26, 2018-- Pacira Pharmaceuticals, Inc. today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 3, 2018. The ...

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks3 months ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

  • FDA Okays Label Expansion of Pacira's Exparel's, Stock Up
    Zacks3 months ago

    FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

    Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

  • Market Exclusive3 months ago

    Here’s Why The Latest News Is A Big Deal For Pacira Pharmaceuticals

    Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is drawing a considerable amount of attention in the biotechnology space as we start a fresh week of trading, with the activity rooted in an event that hit press shortly before markets closed out for the session last Friday. Here is what happened. For anybody not familiar with Pacira, this one […] The post Here’s Why The Latest News Is A Big Deal For Pacira Pharmaceuticals appeared first on Market Exclusive.

  • Company News For Apr 9, 2018
    Zacks3 months ago

    Company News For Apr 9, 2018

    Companies in the news are: PSMT,CPB,BWEN,PCRX